Table 1.
Baseline patient characteristics
| All (n = 3,460) | Kidney (n = 2,247) | Liver (n = 718) | Pancreas/SPK (n = 495) | |
|---|---|---|---|---|
| Age (y) | 49.9 +/− 12.4 | 50.9 +/− 13.0 | 53.6 +/− 9.7 | 40.1 +/− 7.6 |
| Body Mass Index (kg/m2) | 27.6 +/− 5.5 | 27.8 +/− 5.3 | 28.9 +/− 6.3 | 24.9 +/− 3.8 |
| Female (%) | 39.1 | 39.5 | 36.5 | 40.9 |
| African American (%) | 7.2 | 9.5 | 2.1 | 4.2 |
| Diabetes (%) | 31.7 | 26.8 | 0 | 99.8 |
| Cyclosporine (%) | 28.3 | 40.1 | 8.1 | 3.8 |
| Tacrolimus (%) | 61.3 | 45.4 | 89.1 | 92.9 |
| Azathiopurine (%) | 0.4 | 0.4 | 0.6 | 0.2 |
| Mycophenolate mofetil (%) | 89.5 | 94.9 | 67.7 | 96.4 |
| Delayed Graft Function (%) | NA | 17.5 | NA | NA |
| MELDa | NA | NA | 20.46 +/− 9.08 | NA |
| Simultaneous Pancreas and Kidney (%) | NA | NA | NA | 90.5 |
a
MELD - Model End Organ Liver Disease,
NA=Not Applicable)